Magnesium Sulfate in Pediatric Burn Dressing Changes

Inclusion Criteria:

* \< 18 years old at time of randomization completion
* admission to HCMC Burn Unit
* Projected multi-day sedated dressing change requirement
* Intention for IV Ketamine as primary analgosedative agent

Exclusion Criteria:

* age \< 3 years (may lower pending FDA discussions)
* Evidence of hypermagnesemia - pre-study serum Mg2+ level \> 2.5 mg/dL
* Evidence of renal dysfunction - serum Cr level \> 1.5x hospital upper limit normal for age
* Presence of neuromuscular disease (specifically myasthenia gravis), underlying bradyarrhythmia or heart block
* Bronchospastic disease (asthma, reactive airway disease) which requires continuous magnesium sulfate infusion
* Active prescription of a calcium channel blocker (amlodipine, isradipine, nicardipine, nifedipine, clevidipine, diltiazem, verapamil), cardiac glycoside (digoxin), parenteral nutrition or an infusion for hemodynamic support (epinephrine, norepinephrine, dopamine, dobutamine, milrinone, etc)
* Known allergy or reaction to magnesium sulfate, aluminum, or a component of the formulation
* Presence of invasive mechanical ventilation
* Anticipation of skin grafting within 5 days of study eligibility
* Anyone whom child protective services are consulted
* Any investigational drug use within 30 days prior to enrollment
* Pregnant or lactating females
* Anyone whom in the opinion of the investigator is at higher than anticipated risk of harm or inability to adhere to protocol
* Patients who choose to opt out of research